DOR BioPharma, Inc. (OTC BB: DORB)

DOR BioPharma, Inc. (OTC BB: DORB), a late-stage biopharmaceutical company, is committed to developing products that treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases; in addition to vaccines for certain bioterrorism agents. orBec®, DOR’s lead product, is a potent, locally acting corticosteroid being developed to treat gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. For further information, visit the Company’s web site at www.dorbiopharma.com.